Interleukin 13 and its role in gut defence and inflammation

Peter Mannon,¹ Walter Reinisch²

¹Division of Gastroenterology and Hepatology, University of Alabama at Birmingham, Birmingham, Alabama, USA

²Department of Medicine IV, Division Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria

Correspondence to

Dr P Mannon, Division of Gastroenterology and Hepatology, University of Alabama at Birmingham, 1825 University Blvd., SHEL613, Birmingham, AL 35294, USA; pmannon@uab.edu
Published Online First
1 September 2012

ABSTRACT

Interleukin 13 (IL-13) is a cytokine of increasing interest to gastroenterologists because of its developing role in ulcerative colitis, eosinophilic oesophagitis (EO) and fibrosis. Recent data show that IL-13 may play an important role in a novel innate immune response since it can be released by signals from an injured or inflamed epithelium, of particular relevance to the gut. Animal models of IL-13-driven inflammation (from asthma to colitis and EO) are being translated to human disease and providing insight into potential strategies for new therapies. In fact, multiple clinical trials using anti-IL-13 drugs are underway in asthma and are being extended to gastrointestinal diseases. This review presents the current knowledge on IL-13 production and function in the gut, including the cells and receptor signalling pathways involved in mediating IL-13 effects, the proposed mechanisms of IL-13 induced gut disease and the many drugs currently being tested that target IL-13 related pathways.

INTRODUCTION

Interleukin 13 (IL-13) is a cytokine increasingly recognised for novel roles in allergic and other inflammatory conditions. Like many components of the immune response, IL-13 has a physiological role in fighting infection—that is, eliminating helminthic parasites from the intestine—but it also can exert pathological effects when excessively produced. IL-13 has been cited as a component of different types of mucosal inflammation, including allergic asthma, ulcerative colitis, eosinophilic oesophagitis (EO) and several diseases with an important component of fibrosis. Currently, there is a large effort to test anti-IL-13 strategies in the clinic, mostly driven by the proposed role of IL-13 in asthma but also by the discovery of its contribution to other diseases. This review will focus on the IL-13 cytokine and receptor pathways, the role of IL-13 in gut mucosal immune responses and inflammatory diseases, and highlight development and testing of drugs targeting IL-13 and the IL-13 receptor system.

IL-13 AND ITS RECEPTORS

IL-13 is a 33 amino acid peptide cytokine whose gene resides on human chromosome 5q31. It is located within a cluster of cytokine genes that includes IL-3, IL-4, IL-5 and granulocyte-macrophage colony stimulating factor (GM-CSF)¹: it has only 25% homology with IL-4 but is structurally similar. IL-13 transcription is regulated by GATA3 (the classical Th2 cell transcription factor), the

hedgehog pathway (in a murine model) and intergenic mechanisms involved with tissue specific expression.^{2–3} A Th2 family cytokine (along with IL-4 and IL-5), IL-13 is produced by CD4 T cells that are the adaptive effector cells active in allergic asthma. However, in humans, innate immune cells such as eosinophils, basophils, mast cells, natural killer (NK) cells and NK T cells (see below, highlighted in ulcerative colitis), have also been reported to have a capacity to produce IL-13.^{4–7} Recently, several novel IL-5- and IL-13 secreting cell types with innate immune function and negative for B and T cell markers were recovered from murine small bowel, gut associated lymphoid tissue and abdominal fat associated lymphoid tissue.⁸ A potentially important connection between these IL-13 secreting innate lymphoid cells and the gut is that IL-13 production can be stimulated by gut epithelial derived signals such as IL-33, IL-25 (IL-17E) and thymic stromal lymphopoietin (TSLP) that are themselves released in response to inflammation and infection.^{9–12} These innate lymphoid cells may be a source of IL-13 release in reaction to signals that do not require the presence of B or T cells.^{13–14} These so-called innate helper cells or innate lymphoid cells have a human homologue that can be isolated from peripheral blood but has not yet been located in the gut.¹⁵ So while IL-13 production in the human gut in response to helminth infection is assumed to be predominantly from Th2 type CD4 cells, different cells, like the NK T cell or even the innate lymphoid cell, may contribute significantly to the induction and maintenance of chronic idiopathic intestinal inflammation.

IL-13 binds to two cell surface receptors but predominantly signals through just one. The IL-13R α 1 receptor protein can bind IL-13 with low affinity, but on dimerising with IL-4R α , it forms the type 1 IL-13 receptor, enhancing its affinity for IL-13 and transducing intracellular signals through phosphorylation of signal transducer and activator of transcription (STAT) 6 via Jak kinases (figure 1). The type 1 IL-13R α 1/IL-4R α receptor binds both IL-13 and IL-4 (although IL-4 can also signal through the IL-4R α /common γ chain receptor). Although STAT6 seems to be the main signalling molecule in the type 1 IL-13R pathway, other second messenger molecule activation, including phosphatidylinositol 3-kinase (PI3K), STAT3 and mitogen activated protein kinase (MAPK), has been measured in different cell types (although these studies do not specify the types of IL-13 receptors expressed on these in vitro cell models;

Figure 1 Interleukin (IL)-13 receptors and targets of anti-IL-13 and anti-IL-4 agents. The type I IL-13 receptor (IL-13 α 1/IL-4 α heterodimer) signals primarily through Jak2/signal transducer and activator of transcription (STAT) 6 after IL-13 or IL-4 binding. In certain cells, mitogen activated protein kinase (MAPK), STAT3 and phosphatidylinositol 3-kinase (PI3K) may be activated by this receptor. The type II IL-13 receptor (IL-13 α 2 monomer) binds only IL-13 and largely has no signalling although reports exist of MAPK,²⁶ PI3K²⁵ and STAT3²⁷ activation. Novel anti-IL-13 agents being tested for efficacy in IL-13 mediated diseases are shown with their targets: anti-IL-13 antibodies interact with IL-13 (lebrikizumab), either allowing it to interact with the receptors (anrukizumab blocks IL-4 α association with the IL-13/IL-13 α 1 complex) or not (IMA-026); anti-IL-4 α antibody blockade (AMG317 and knockdown of IL-4 α protein (Altair)) disables the IL-13 α 1/IL-4 α heterodimer; and toxin linked mutated IL-13 binds with high affinity to IL-13 α 2, killing the cell once internalised ($\rightarrow$, pathway activation; $\dashv$, pathway blockade).

in the case of HT-29 cells, it is likely that IL-13 α 1 is transducing a variety of downstream signals^{16–19}).

By comparison, the type 2 IL-13 receptor, IL-13 α 2, exists largely as a monomer and has less well defined signalling properties. IL-13 α 2 binds IL-13 with higher affinity than the dimeric type 1 IL-13 α 1/IL-4 α receptor. This difference in binding affinity is relevant because when interacting with the type 1 receptor, IL-13 first binds to the low affinity IL-13 α 1 monomer before dimerising with the IL-4 α receptor, giving an added advantage to the type 2 receptor for capturing IL-13.²⁰ The IL-13 α 2 receptor appears to function largely as a 'sink' for IL-13, binding the cytokine and making it unavailable for activating the type I receptor, while not inducing its own intracellular signal (decoy receptor). Given the ability of IL-13 α 2 expressing cells to clear IL-13 from culture medium, it has also been considered an important scavenging system for IL-13 cytokine, limiting its activity.²¹ Indeed, when the two receptors are co-expressed by a cell, IL-13 induced pSTAT6 production is generally inhibited.²² The mechanism of this inhibition is attributed to the preferential binding of IL-13 to IL-13 α 2 since this inhibition can be overcome with excess IL-13 (exceeding the binding capacity of the IL-13 α 2 receptor). However, other data show that the IL-13 α 2 protein can inhibit IL-4 induced pSTAT6 (in the absence of IL-13; IL-13 α 2 does not bind IL-4) and IL-13 α 2 can physically interact with IL-4 α ,^{23 24} suggesting that the IL-13 α 2 can mediate inhibition of type 1 receptor signalling by additional mechanisms beyond merely scavenging IL-13. While the IL-13 α 2 receptor has a short intracellular portion that lacks recognised binding sites for signalling molecules, there are some reports connecting IL-13 α 2 receptor binding to intracellular signals (STAT3, MAPK, PI3-K) but it is unknown whether this is a direct mechanism or through

additional binding of scaffold proteins to the intracellular portion.^{25–27} An additional curiosity about the IL-13 α 2 is that in mice, this monomeric protein can exist as a soluble protein capable of binding IL-13, the result of alternative splicing of the IL-13 α 2 gene.^{28–30} However, a soluble form of this receptor protein does not appear to be active in humans (despite the fact that its extracellular protein structure makes it susceptible to release by cell surface proteases).

The IL-13 pathway is regulated at a number of points. Its transcription and production can be positively regulated by GATA3 and the hedgehog pathway, and negatively regulated by cytokines such as type 1 interferons.³¹ Furthermore, the IL-13 α 2 receptor can be seen as a negative regulator of IL-13 effects since IL-13 exposure leads to its transcriptional upregulation and expression, the IL-13 α 2 receptor rapidly cycles from intracellular locations to capture and internalise IL-13 and IL-13 α 2 receptor expression is inversely related to IL-13 STAT6 activation.^{22 32 33} Lastly, IL-13 signalling via the Jak/STAT pathway can induce suppressor of cytokine signalling proteins that actually attenuate the IL-13 signal itself.³⁴ Identifying the factors that result in dysregulation of IL-13, its receptors and their signal transduction will give great insight into the pathogenesis of allergic asthma and other IL-13 associated inflammatory diseases.

IL-13 IN THE GUT MUCOSAL IMMUNE RESPONSE

As a component of the gut mucosal immune response, IL-13 has been recognised primarily for its role in the inflammatory reaction to helminthic infections. IL-13 works at a number of levels to combat this infection, stimulating mucus production from goblet cells, inducing local eotaxin release to attract eosinophils and increasing IgE production (all responses resembling

IL-13 induced airway pathology in experimental allergic asthma), as well as possibly contributing to increased gut motility and epithelial secretion (via disruption of the tight junction and possibly enhanced cystic fibrosis transmembrane conductance regulator mediated apical chloride secretion^{35–36}). IL-13 is important to antihelminth immunity since IL-13 knockout mice (and IL-4R α and STAT6 deficient, but not IL-4 deficient mice) have significantly longer parasite expulsion times after experimental intestinal nematode infection.^{37–38}

Murine models show that in helminth infections, CD4⁺ T cells are the source of gut mucosal IL-13. In fact, CD4 cells from *Trichuris muris* infected wild-type mice (harvested at the peak of Th2 cytokine production) can transfer resistance to infection in SCID (T and B cell deficient) mice.³⁹ In humans, a recent report documented the induction of Th2 cytokine production following experimental hookworm infection in naïve persons; subjects developed peripheral blood memory T cells that produced IL-13 in a helminth antigen specific manner.⁴⁰ No early innate IL-13 response to helminthic infection was observed in these naïve subjects but an adaptive IL-13 response clearly developed. It is not known whether innate responses specific to the gut (compared with peripheral blood) are active in helminth naïve or helminth experienced persons. Despite adaptive IL-13 responses and induced tissue eosinophilia however, humans infected with helminths usually do not eliminate the worms entirely.

IL-13 producing cells can be found in the healthy and non-inflamed human lamina propria, and IL-13R α 1 is expressed constitutively in gut epithelium, but it is unknown whether IL-13 plays an important homeostatic role or is only roused to action by infection or injury. On the one hand, human and mouse cells show that IL-13 can limit Th17 inflammation by blocking IL-17 (A) production by increasing IL-10 (in a murine model), suggesting perhaps a homeostatic role in the gut.^{41–43} On the other hand, IL-13 may play a role in limiting evolving colitis injury: the IL-10 knockout mouse is susceptible to severe *T. muris* gut infection but when the IL-13R α 2 decoy receptor is also deleted, effectively increasing the bioavailability of IL-13, there is significant protection from mortality and induction of colitis.⁴⁴ Interestingly, this protective effect of IL-13 is also associated with inhibition of IL-17 production. Th17 cells have been shown to express IL-13R α 1, and IL-13 can inhibit Th17 development from naïve T cells (not surprising perhaps, given the same effect of IL-4 previously described, possibly acting through the same type 1 receptor). So endogenous IL-13 may have a dual role of protecting against excess IL-17 effects in the gut and limiting colitogenic processes. IL-13 pretreatment is also effective at limiting ischaemia–reperfusion injury of the murine small bowel associated with inhibiting inflammatory cytokines, consistent with similar effects on inflammatory cytokine activity in the gut and periphery.^{45–47} Conversely, when IL-13 is deliberately overexpressed in the murine gut, epithelial remodelling and dysfunction occurs. Linked to the fatty acid binding protein intestinal promoter, increased IL-13 expression by the small intestinal epithelium is associated with goblet cell hyperplasia (and mucus hypersecretion), villus shortening, epithelial cell hyperproliferation (without increased apoptosis) and cystic fibrosis transmembrane conductance regulator upregulation with increased apical chloride secretion.³⁵ Interestingly, this condition was not associated with apparent inflammation (B and T cell numbers and T cell activation markers were similar to wild-type mice). This lack of accompanying inflammation could be related to the facts that the epithelium (and not immune cells) was the source of the IL-13

and there was a concomitant increase in soluble IL-13R α 2 that could have controlled local activity of IL-13; it could also be due to enhanced Paneth cell function (not measured) and the relative lack of microbial load in the small intestinal lumen.

Little is known about the expression of IL-13 receptors in the gut, pointing out sites where IL-13 could exert effects. In the mouse gut, the IL-13R α 1 gene is expressed in the epithelium, myenteric plexi and smooth muscle layers of the small bowel and colon, whereas the IL-13R α 2 gene was solely and highly expressed in smooth muscle.⁴⁸ Expression of IL-13R α 1 is seen in epithelial cells isolated from non-inflamed human colon (IL-13 exposure induces phospho-STAT6 as well as transient increases in phospho-MAPK and phospho-p38MAPK) while IL-13R α 2 is expressed at very low levels if at all.^{49–50} In ulcerative colitis, colonic epithelial cells can show an increased expression of both receptors,⁴⁹ and in Crohn's disease with fistula formation, IL-13R α 1 receptor protein has increased expression in myofibroblast-like and epithelial-like cells lining, and adjacent to, fistula tracts.⁵¹ So there are sites where IL-13 can induce contractility, mucus production and increased secretion to fight helminth infection in the normal gut, but information on receptors on gut associated immune cells and tissue structures is lacking. One challenge to defining IL-13 and its role in gut mucosal immunity lies in identification of the cell phenotypes that provide the IL-13, whether a traditional Th2 T cell (making IL-4, IL-5 and/or IL-13), NK cells within the epithelium,⁵² NK T cells in the lamina propria or the innate helper cell that can secrete high levels of IL-13 in response to epithelial derived cytokines. Another challenge involves delineating both the protective and injurious effects that IL-13 exerts in the gut wall and whether these thresholds are determined by acquired (during an infectious or inflammatory event) or genetic factors.

IL-13 AND HUMAN DISEASE

The prominent role of IL-13 in allergic asthma models and excess IL-13 production in human asthma are currently driving the development and testing of anti-IL-13 compounds in clinical trials. Animal models of allergic asthma clearly show that IL-13 unresponsive mice are resistant to allergen induced airway hyperresponsiveness and the ensuing inflammatory changes.^{53–54} Now that early reports support the efficacy of anti-IL-13 antibodies for human asthma,^{55–56} other conditions that implicate IL-13 in their pathogenesis may also benefit from this drug pipeline. For example, IL-13 may be an effector cytokine in fibrotic diseases, from idiopathic pulmonary arterial hypertension to progressive systemic sclerosis.^{19–57–59} Below we review the association of IL-13 with several gastrointestinal inflammatory diseases, ulcerative colitis, EO and the fibrosis associated with Crohn's fistulous disease.

Ulcerative colitis

IL-13 has become the leading candidate effector cytokine driving inflammation in ulcerative colitis based on data from a murine model of ulcerative colitis, from subsequent confirmation of excess IL-13 production in human disease and from establishment of biologically plausible mechanisms of IL-13 induced gut injury using in vitro colonic epithelial (colon cancer) cell lines. In the oxazolone model of colitis, following skin sensitisation with the haptenating agent oxazolone, oxazolone is administered intrarectally in an alcohol vehicle; this induces an immune mediated inflammatory response to haptenated microbial antigens that access the lamina propria via an ethanol damaged epithelial barrier. The histopathological appearance closely resembles ulcerative colitis, particularly since

the inflammation is limited to the mucosa.⁶⁰ After a short lived increase in IL-4, the hallmark cytokine of the Th2 response, there is a significant increase in IL-13 produced by lamina propria mononuclear cells. An innate immune cell, the NK T cell, was identified as the source of the IL-13 and found to be the major contributor to the inflammation since the lesion could be prevented by administration of an IL-13R α 2-Fc fusion protein (neutralising secreted IL-13) as well as by depleting mice of NK T cells or the cell surface molecule that presents specific antigens to the NK T cells (CD1 in mice, CD1d in humans).⁶¹ Furthermore, when lamina propria mononuclear cells were stimulated with the invariant NK T cell specific antigen, α -galactosylceramide, the amount of IL-13 secreted was similar to polyclonal T cell receptor stimulation, suggesting that nearly all the IL-13 was derived from NK T cells. Interestingly, after intratracheal α -galactosylceramide analogue administration to mice, NK T cells directed lung dendritic cells to induce a Th2 inflammatory (IL-4, IL-5 and IL-13) T cell response to other antigens (although the NK T cell itself was not characterised as a source of IL-13), suggesting that NK T cells can be involved at different points in the induction of innate IL-13 responses.⁶² More recently, investigators showed that not only was IL-25 (IL-17E) expression increased in colonic epithelium in oxazolone treated mice, but pretreatment blockade of IL-25 binding to lamina propria mononuclear cells (including T cells, NK T cells and a population of cells thought to contain non-T, non-B innate lymphoid cells) inhibited IL-13 production and prevented colitis.⁶³ These data suggest that while IL-13 might be a valuable target for novel therapy in ulcerative colitis, targeting the factors that regulate its production during inflammation may also be a useful strategy.

Observations in human disease show that patients with active ulcerative colitis produce significantly higher amounts of IL-13 from lamina propria mononuclear cells and increased epithelial pSTAT6 compared with active Crohn's patients and healthy controls.^{4 64} Moreover, NK T cells appear to be the major source of IL-13 from the inflamed ulcerative colitis mucosa, but the cells are not of the majority type I invariant NK T cell population; instead they appear to be from the NK T cell type II that are non-invariant (ie, not sharing the V α 24J α 14 TCR chain and not stimulated by α -galactosylceramide) but respond to stimulation by CD1d expressing cells (presumably loaded with endogenous glycoprotein antigens).

The excessive production of IL-13 in ulcerative colitis is thought to lead to its deleterious effects, particularly as IL-13 has demonstrated toxic effects on colonic epithelial cells and the epithelial barrier. IL-13 activates the proapoptotic molecule caspase 3 in mouse colonic epithelial cells, a process involving the tumour necrosis factor superfamily cytokine TWEAK as well as tumour necrosis factor α itself, all proteins found to have increased expression in patients with active ulcerative colitis.⁶⁵ During acute exposure of gut epithelial cells modelled by the HT-29/B6 differentiated subclone of the well known colon cancer cell line, IL-13 can also induce epithelial cell apoptosis, inhibit movement of epithelial cells across a denuded area (interpreted as blocking restitution of the cell monolayers) and disrupt the tight junction by inducing a component, claudin 2, that interferes with the structured tight junction protein complex.⁵⁰ In fact, studies of the *T. spiralis* nematode infection in mice directly linked IL-13 and IL-13 signalling through the type 1 receptor (produced by CD3⁺ intraepithelial NK cells) to villus blunting and Goblet cell hyperplasia that can occur even in the absence of B and T cells.⁵²

Overexpression of IL-13 in the inflamed mucosa of ulcerative colitis is a unique characteristic of this inflammatory bowel disease. What is less clear is how this inflammation begins. Is there an initial inflammation or injury that induces an innate IL-13 response that becomes uncontrolled or is there an induction of memory Th2 CD4 cells that contribute to ongoing and recurrent antigen specific responses? Studies of cytokine production in ulcerative colitis show that IL-13 is the predominant Th2 cytokine secreted along with IL-5 but without IL-4, consistent with an innate cell source (NK T or innate helper cell) versus a classical Th2 CD4 cell. However, it is still unclear whether there is dysregulation in the IL-13 cytokine and receptor pathways that predisposes to disease. Since IL-13R α 2 deficient mice have amplified responses to IL-13,⁶⁶ genetic defects in the IL-13 receptor system have been studied in asthma and fibrosis where excess IL-13 activity could mediate disease. One association with asthma and atopy is the IL-13 variant, Arg130Gln, that produces an IL-13 peptide that still activates the IL-13R α 1 receptor but has lower affinity for the IL-13R α 2 receptor⁶⁷ giving a phenotype that would be predicted to enhance IL-13 effects.^{68–72} Furthermore, polymorphisms in the IL-13R α 2 gene that could affect the binding of transcription factors are significantly associated with systemic sclerosis patients⁶⁹ but there are no functional data to explain any of these effects on IL-13R α 2 expression. One small study in ulcerative colitis patients failed to show disease association with the Arg130Gln IL-13 variant.⁷² However, in one study of infliximab treatment response (one or three infusions) in ulcerative colitis patients, IL-13R α 2 gene expression in colonic biopsies was found to be significantly higher in non-responders (defined as no endoscopic and histological healing) compared with responders.⁷³ Since tumour necrosis factor can induce IL-13R α 2 RNA,⁷⁴ this finding makes sense, but whether this subset of patients represents one with more intense IL-13 production (contributing to increased IL-13R α 2 gene expression) or dysfunction of the IL-13R α 2 receptor protein (higher expression should blunt IL-13 activity) is unknown. Finally, a pilot study looking at the effects of type I interferon treatment on ulcerative colitis showed that only treatment responders had significant decreases in IL-13 production; the non-responders showed no change in IL-13 production and also had significantly higher pretreatment production of IL-17.⁷⁵

Eosinophilic oesophagitis

Eosinophilic oesophagitis (EO) is an increasingly recognised disease characterised by marked eosinophilic infiltration (≥ 15 eosinophils/high power field) of the oesophageal mucosa with clear links to allergic inflammatory states.⁷⁶ There are many examples from animal models of an IL-13 role in the induction of the typical lesion of EO. For instance, eosinophilia of the oesophagus followed nasal or tracheal administration of IL-13, and this outcome could be blocked in IL-5 deficient mice.⁷⁷ Following aeroallergen induction of an EO-like lesion, both IL-13 and STAT6 deficient mice were protected from developing the oesophageal inflammation.⁷⁸ Similarly, targeted overexpression of IL-13 in the lungs resulted in oesophageal eosinophil infiltration as well as oesophageal tissue remodelling (macroscopic increase in the oesophageal circumference, increased collagen deposition, epithelial cell layer hyperplasia and angiogenesis).⁷⁹ After incubation with IL-13, isolated murine oesophageal tissue produced potent, STAT6 dependent chemotactic factors for eosinophils (CCL11 (eotaxin-1) and CCL24 (eotaxin-3)), important in the development of EO.⁸⁰ In human

disease, cytokine expression in EO shows significant upregulation of IL-13 and IL-5 expression as well as IL-13/STAT-6 induced chemokines such as eotaxin-3 and CCL23.⁸¹ Significantly elevated IL-13 and IL-5 levels can be detected in the plasma of children with EO and food allergy.⁸² These data link IL-13 to the development of EO in animal models and confirm similar cytokine disturbances in human disease. Further work will need to be done on the contribution of allergic, or IL-5 dependent, inflammation to EO and understanding what the hierarchy of cytokine contributions are in driving the eosinophilia and tissue remodelling which may occur by independent mechanisms (important for planning therapy and predicting non-response).

The pathogenesis of EO seems to be linked to allergen hypersensitivity, and given the familial association of EO, atopy and food allergy, a genetic component may be contributing to disease susceptibility. Several genes and gene loci have been identified as risk variants in EO using a candidate gene approach, including the 3' untranslated region of eotaxin (*CCL26*), the transforming growth factor (TGF) β 1 promoter, a filaggrin (*FLG*) exon and a TSLP intron and TSLP receptor (*CRLF2*) exon.⁸³ These associations make sense because eotaxin is excessively expressed in EO mucosa, FLG is a structural skin protein that helps to maintain barrier function (and is downregulated by IL-13) and TSLP has been shown to stimulate IL-13 production by innate helper cells in the lamina propria.⁸⁴ However, it is still unclear how these genetic polymorphisms translate to dysfunction of the IL-13 pathway in mediating susceptibility to EO.

Intestinal fibrosis

Tissue fibrosis is a recognised outcome of IL-13 exposure, including progressive systemic sclerosis,⁸⁵ hepatic fibrosis⁸⁷ and idiopathic pulmonary fibrosis.⁸⁸ IL-13 has been linked to the tissue remodelling seen in animal models of allergic asthma,⁷⁹ EO and bleomycin induced pulmonary fibrosis.⁹⁰ Interestingly, in the 2,4,6-trinitrobenzenesulfonic acid (TNBS) model of colitis in mice, typically a model of Crohn's disease in the early days after TNBS administration, chronic intrarectal administration of the haptenating agent progresses to an IL-13 dominant cytokine production profile. This increase in IL-13 production is accompanied by colonic fibrosis that is mediated by TGF β , since blocking TGF β abrogated the fibrosis. IL-13 itself had been previously recognised as inducing fibrosis via TGF β following targeted overexpression of IL-13 in the lung.⁹¹ So the chronic TNBS model demonstrates how fibrosis can occur following IL-13 production in the intestine, and while fibrostenotic complications of ulcerative colitis are generally low, fibrosis is recognised as a complication of longstanding ulcerative colitis and healing is associated with pronounced scarring.^{92–94} On the other hand, where fibrostenotic complications are a hallmark of Crohn's disease, a role for IL-13 is emerging in the formation of fistulae. A recent report demonstrates that IL-13 is highly expressed in so-called transitional cells that line fistula tracks, and that IL-13 induces genes involved in cell invasion, presumably a mechanism of fistula formation through tissue⁵¹; interestingly, TGF β was also highly expressed and induced IL-13 production by lamina propria fibroblasts. These observations support IL-13 as a target for antifibrotic therapies in certain settings.

Additional IL-13 effects in the GI tract

The role of IL-13 regulated intestinal contractility as a contributing mechanism for helminth expulsion has interested groups

studying motility disorders. Whereas IL-13R α 2 is dominantly expressed in murine gut smooth muscle, it is observed that IL-13R α 2 deficient mice have hypercontractile responses to acetylcholine.⁴⁸ This hypercontractility is induced by *Nippostrongylus brasiliensis* infection where epithelial derived IL-25 drives the IL-13 and muscle responses.⁹ Hypercontractility of the muscularis propria is seen in mouse gut after infection with parasites or after polyclonal T cell stimulation, suggesting that cytokines, including IL-13, could be contributing to the stimulation of gut smooth muscle.⁹⁵ Clearly this could be applied to hypotheses about the aetiology of post-infectious irritable bowel syndrome. It is not known whether IL-13 receptors are similarly expressed in human gut smooth muscle (although they are detected in the smooth muscle of the human pulmonary artery) but IL-13 was produced at significantly higher levels by stimulated peripheral blood lymphocytes isolated from patients with functional gastrointestinal disorders (irritable bowel syndrome, functional dyspepsia and non-cardiac chest pain) compared with normal controls.⁹⁷

DEVELOPMENT OF ANTI-IL-13 DRUGS

In light of the central role IL-13 appears to be playing in allergic asthma, including lung eosinophilia, epithelial hypertrophy, mucus hyperproduction, inflammation, hyperresponsiveness and remodelling of the airway, many companies are developing and testing anti-IL-13 strategies as novel therapeutics, taking advantage of some of the pharmacological aspects of IL-13 and its receptor system (see table 1). The most common strategy is to develop an antibody against IL-13 that can bind to the soluble form of the cytokine and prevent it from binding to its primary signalling molecule IL-13R α 1 but also to IL-13R α 2. For instance, there are several antibodies directed against IL-13 that disrupt binding to the receptors, including anrukinzumab, lebrikinumab and tralokinumab; in general, this strategy blocks all IL-13 signalling but will allow IL-4 to signal through the type 1 receptor as well as the alternate IL-4R α / γ_c receptor.⁹⁸ There can be different mechanisms of action resulting from antibody design to the same protein however. For instance, IMA-026 and anrukinzumab are antibodies directed against non-shared epitopes of IL-13. Whereas IMA-026 blocks the binding of IL-13 to IL-13R α 1 and IL-13R α 2, anrukinzumab permits binding of IL-13 to IL-13R α 1 and IL-13R α 2 but inhibits formation of a IL-13R α 1 complex with IL-4R α ; both antibodies prevent activation through the IL-13R α 1/IL-4R α receptor, but while IMA-026 potentially interferes with IL-13 uptake and internalisation by the IL-13R α 2 receptor, anrukinzumab only does so partially (and the IL-13-anrukinzumab complex still can be internalised through the IL-13R α 2).²¹ So use of the IMA-026 antibody can bind IL-13 but result in higher detectable circulating IL-13 (presumably antibody bound, biologically inactive IL-13) in treated patients.⁵⁶

There is a strategy to block access to IL-4R α , thereby blocking IL-13 and IL-4 engagement of the IL-13R α 1/IL-4 α receptor complex (and IL-2R- γ_c receptor). This strategy might enhance IL-13 binding to the IL-13R α 2 receptor whose decoy/scavenging activity could enhance anti-IL-13 effects or enhance IL-13 signals through IL-13R α 2, depending on the cell type and surface expression of IL-13R α 2. Another anti-IL-13 agent has been developed to target the IL-13R α 2 receptor specifically, since IL-13 plays a role as a growth factor for certain malignancies which express IL-13 receptors; in this case, agents are developed to destroy the IL-13R α 2 bearing cell, for instance using an endotoxin linked to a mutated IL-13 protein that preferentially binds to the IL-13R α 2 and can kill the cell on internalisation.¹⁰⁰

Table 1 Drugs in development targeting interleukin 13 or its receptors

Inhibitor	Company	Isotype	Mode of mechanism	Route	Clinical data
Anti-IL-13 MILR1444A Lebrikizumab	Roche/ Genentech	IgG4, κ , with stabilising point mutations	Binds to human IL-13 and inhibits IL-13 induced phosphorylation of STAT6 in TF-1 cells	sc	Positive phase 2 study in patients with adult asthma despite inhaled glucocorticoid therapy (NCT00930163). Monthly treatment with 250 mg improved FEV ₁ at week 12. Reductions in serum Th2 chemokines (CCL13, CCL17) and IgE were observed. ⁵⁵ Phase 3 studies in patients whose asthma is uncontrolled with inhaled corticosteroids and a second controller medication (LUTE, NCT01545440 and VERSE, NCT01545453) are ongoing, with primary end point being exacerbations during the 52 week placebo controlled period.
Anti-IL-13 CAT-354 Tralokinumab	Medimmune/ Astra Zeneca	IgG4, λ	Neutralises IL-13	sc	Phase 2 randomised, double blind, placebo controlled study in moderate to severe asthma (NCT00873860) showed improved FEV ₁ at week 13, but no improvement in ACQ-6 score. ¹⁰² A phase IIa, randomised, double blind, placebo controlled, parallel arm, multicentre study to evaluate the efficacy and safety of tralokinumab (every 2 weeks for 12 weeks) as add on therapy, on clinical response in patients with active, moderate to severe, ulcerative colitis is ongoing (NCT01482884).
Anti-IL-13 QAX-576 Fully human	Novartis	IgG1, κ	Specific inhibitor of human IL-13 activity	iv	A double blind, placebo controlled study showed reduced IL-13 responses in intranasal grass pollen challenge model, with possible effect on total nasal symptom scores in subgroup with high late phase nasal IL-13 levels at screening (NCT00584584). ¹⁰³ Phase 2 programmes are ongoing in moderate to severe asthma (NCT01130064) and idiopathic pulmonary fibrosis (NCT01266135). A phase 1 study on the sequential administration of a fixed dose of the anti-IL-4 antibody, VAK694, and single ascending doses of QAX576 in patients with well controlled mild to moderate asthma is completed (NCT01568762). In NCT01316601 the efficacy, safety and tolerability of QAX576 in the treatment of perianal fistulas in patients suffering from Crohn's disease is assessed. In patients with eosinophilic oesophagitis, the effects of a 12 week course of iv QAX576 6 mg/kg every 4 weeks is tested to reduce the number of eosinophils in the oesophagus (NCT01022970). The study has been completed, but results are pending
Anti-IL-13 ABT-308	Abbott		Blocks IL-13 interaction with IL-13R α 1/ α 2 ¹⁰⁴	sc and iv	Phase 1 in patients with mild to moderate asthma is completed (NCT00986037)
Anti-IL-13 IMA-026 Humanised	Pfizer	IgG1, κ	Specific for IL-13 epitope that binds IL-13R α 1 and IL-13R α 2	sc	In phase 2 no significant effects on allergen induced late phase asthmatic response or sputum eosinophils could be observed (NCT00725582) ⁵⁶
Anti-IL-13 IMA-638 Anrukinzumab	Pfizer	IgG1, κ	Inhibits formation of a IL-13R α 1 complex with IL-4R α	sc and iv	In phase 2 (NCT00410280), an attenuated early (19%) and late allergen induced asthmatic response (24%) was described in patients with mild atopic stable asthma. ⁵⁶ A phase 2a study is recruiting patients with active ulcerative colitis and evaluates proof of mechanism of multiple iv doses of anrukinzumab by changes in mechanism based biomarker and pharmacodynamic biomarkers (NCT01284062)
Anti-IL-13 CNTO-5825 Fully human	Centocor	IgG1, κ	Neutralising IL-13	sc and iv	A randomised, placebo controlled, double blind phase I study to assess the safety, tolerability, immune response, pharmacokinetics and pharmacodynamics in healthy volunteers and healthy atopic volunteers is completed (NCT01081691)
IL-4 IL-13 targeted					
Anti-IL-4R SAR231893 (REGN668)	Sanofi/ Regeneron	IgG	Binds to IL-4R which blocks the function of IL-4 and IL-13	sc	A phase 2 study on once weekly injections for 12 weeks vs placebo on reducing the incidence of asthma exacerbations in patients with persistent moderate to severe eosinophilic asthma is ongoing
Anti-IL-4R α antagonist AMG-317 Fully human	Amgen	IgG2a	Binds to IL-4R α , which competitively blocks the function of IL-4 and IL-13	iv and sc	In a phase 2, randomised, double blind, placebo controlled study, patients received weekly sc injections of AMG 317 (75–300 mg) for 12 weeks. The primary end point, change from baseline at week 12 in ACQ symptom score, was not met in the total patient population. Patients with highest baseline ACQ were more likely to respond. ¹⁰⁵ Significant IgE response in population pharmacokinetic model by fitting data from four early phase clinical trials ¹⁰⁶

Continued

Table 1 Continued

Inhibitor	Company	Isotype	Mode of mechanism	Route	Clinical data
IL-4/IL-13 bispecific DvD-Ig SARI56597	Sanofi	DvD-Ig (dual variable domain Ig)	Bispecific antibody which simultaneously binds both IL-4 and IL-13	sc	At Protein Engineering Summit May 2012, presentation on allergen induced airway hyperresponsiveness in monkeys, and on safety, tolerability and pharmacokinetics of single sc doses of SARI56597 in healthy human subjects (phase 1). Randomised, double blind, placebo controlled study of the safety, tolerability, pharmacokinetics and pharmacodynamics of ascending repeated doses in patients with idiopathic pulmonary fibrosis ongoing; orphan drug status granted by FDA
IL-4 mutein Pitrakinra	Aerovance/Bayer	Similar to native IL-4 molecule, but with 2 amino acid changes (R121D/Y124D), thus competing for IL-4R α	Binds to the IL-4R α subunit and prevents the inflammation induced by IL-4 and IL-13	Inhaled (sc)	In phase 2a study with inhaled compound diminished late phase asthmatic response to allergen challenge in asthmatic patients. ¹⁰⁷ Double blind, randomised, placebo controlled, multicentre trial in patients with uncontrolled, moderate to severe asthma did not reveal a difference in incidence of asthma exacerbations vs placebo after 12 week treatment period. Patients with blood eosinophilia > 350 cells/mm ³ showed lower incidence of exacerbation. ¹⁰⁸ 109 Better activity in subjects with IL-4R polymorphism ¹¹⁰
AIR-645	ISIS/Akair	IL-4R α 2'-O-methoxyethyloligonucleotide antisense RNA	Targets the mRNA that encodes the α subunit of the human IL-4R	Inhaled	Positive safety profile, sputum half life ~ 5 days in sputum. ¹¹¹ Following repeated inhalation, evidence of reductions in serum total IgE, sputum eosinophils in mild asthmatics. ¹¹² Not enough activity in ph2 mild atopic asthma to warrant further development
(Anti IL-4/Anti IL-13 combo) OBX258	Novartis	Ab combo	Blocking IL-4 and IL-13	iv	Anti IL-4 Ab VAK694, in studies of allergic rhinitis. Anti IL-13 Ab QAX576 (see above)

ACQ, Asthma Control Questionnaire; FEV₁, forced expiratory volume in 1 s; IL, interleukin; iv, intravenous; sc, subcutaneous;

ANTI-IL-13 TRIALS

To date, most of the trials in humans using anti-IL-13 agents have been done in asthma with varying degrees of success. A phase 2 study of adult patients with active asthma despite inhaled glucocorticoid therapy treated with 250 mg of lebrikizumab subcutaneously each month showed significant improvement of forced expiratory volume in 1 s at week 12. This effect was more pronounced in a subgroup of patients with high periostin (an IL-13 inducible gene), indicating perhaps even more anti-inflammatory activity for lebrikizumab in patients with higher IL-13 activity. Table 1 lists published and ongoing studies with compounds targeting the IL-13 pathway.

Results from trials using anti-IL-13 agents in patients with inflammatory bowel disease are not yet available. The safety and efficacy of the anti-IL-13 antibody anrukinzumab (IMA 638, Pfizer) is being tested in a phase 2a study in patients with mild to moderate ulcerative colitis. Another phase 2a study is evaluating the efficacy and safety of tralokinumab (CAT-354, MedImmune/Astra Zeneca), a fully human anti-IL-13 antibody in patients with moderate to severe ulcerative colitis. QAX576 (Novartis) is also a fully human anti-IL-13 antibody which is being studied in patients with perianal fistulas from Crohn's disease. Interferon β -1a (Avonex) has previously been used in ulcerative colitis based on the in vitro effects of type I interferons inhibiting IL-13 production from peripheral blood mononuclear cells³¹ and IL-13 intracellular signalling in human monocytes.³⁴ In an open label pilot study that followed immune parameters before and after treatment, 16 patients with active ulcerative colitis were treated for 12 weeks with weekly interferon β -1a.⁷⁵ There was a clinical response rate of >65% at the end of treatment and all responders had a significant decrease in T cell receptor stimulated IL-13 production by lamina propria mononuclear cells (690 vs 297 pg/ml) compared with non-responders (542 vs 510 pg/ml). In a follow-on randomised, placebo controlled phase II study, interferon β -1a (Avonex) 30 μ g subcutaneously twice a week for 12 weeks resulted in a similar significant clinical response at 8 (46% vs 68% placebo vs interferon β -1a; p=0.05) and 12 weeks (52% vs 75%; p=0.01) but no data on changes in cytokines are available.¹⁰¹

SUMMARY

IL-13 is a pleiotropic cytokine both in its cellular sources and in its observed actions. Preclinical and in vitro data point to the involvement of this cytokine in the pathogenesis of chronic inflammatory disorders of the gastrointestinal tract, particularly ulcerative colitis, EO and perianal fistula formation in Crohn's disease. Numerous compounds are available for neutralising IL-13 and activation of its receptor system, of which some have shown biological activity and efficacy in asthma. The study results from anti-IL-13 studies in ulcerative colitis, Crohn's disease and eventually EO are eagerly awaited to further understand the importance of IL-13 in supporting established inflammation of the gastrointestinal tract.

Contributors PM and WR contributed to the researching, writing and review of this manuscript.

Competing interests None.

Provenance and peer review Commissioned; not externally peer reviewed.

REFERENCES

1. McKenzie AN, Li X, Largaespada DA, *et al*. Structural comparison and chromosomal localization of the human and mouse IL-13 genes. *J Immunol* 1993;**150**:5436–44.
2. Rogan DF, Cousins DJ, Santangelo S, *et al*. Analysis of intergenic transcription in the human IL-4/IL-13 gene cluster. *Proc Natl Acad Sci USA* 2004;**101**:2446–51.

3. **Syn WK**, Witek RP, Curbishley SM, *et al.* Role for hedgehog pathway in regulating growth and function of invariant NKT cells. *Eur J Immunol* 2009;**39**:1879–92.
4. **Fuss IJ**, Heller F, Boirivant M, *et al.* Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis. *J Clin Invest* 2004;**113**:1490–7.
5. **Smithgall MD**, Comeau MR, Yoon BR, *et al.* IL-33 amplifies both Th1- and Th2-type responses through its activity on human basophils, allergen-reactive Th2 cells, iNKT and NK cells. *Int Immunol* 2008;**20**:1019–30.
6. **Toru H**, Pawankar R, Ra C, *et al.* Human mast cells produce IL-13 by high-affinity IgE receptor cross-linking: enhanced IL-13 production by IL-4-primed human mast cells. *J Allergy Clin Immunol* 1998;**102**:491–502.
7. **Woerly G**, Lacy P, Younes AB, *et al.* Human eosinophils express and release IL-13 following CD28-dependent activation. *J Leukoc Biol* 2002;**72**:769–79.
8. **Koyasu S**, Moro K. Type 2 innate immune responses and the natural helper cell. *Immunology* 2011;**132**:475–81.
9. **Zhao A**, Urban JF Jr, Sun R, *et al.* Critical role of IL-25 in nematode infection-induced alterations in intestinal function. *J Immunol* 2010;**185**:6921–9.
10. **Pastorelli L**, Garg RR, Hoang SB, *et al.* Epithelial-derived IL-33 and its receptor ST2 are dysregulated in ulcerative colitis and in experimental Th1/Th2 driven enteritis. *Proc Natl Acad Sci USA* 2010;**107**:8017–22.
11. **Beltran CJ**, Nunez LE, Diaz-Jimenez D, *et al.* Characterization of the novel ST2/IL-33 system in patients with inflammatory bowel disease. *Inflamm Bowel Dis* 2010;**16**:1097–107.
12. **Tanaka J**, Saga K, Kido M, *et al.* Proinflammatory Th2 cytokines induce production of thymic stromal lymphopoietin in human colonic epithelial cells. *Dig Dis Sci* 2010;**55**:1896–904.
13. **Fort MM**, Cheung J, Yen D, *et al.* IL-25 induces IL-4, IL-5, and IL-13 and Th2-associated pathologies in vivo. *Immunity* 2001;**15**:985–95.
14. **Yasuda K**, Muto T, Kawagoe T, *et al.* Contribution of IL-33-activated type II innate lymphoid cells to pulmonary eosinophilia in intestinal nematode-infected mice. *Proc Natl Acad Sci USA* 2012;**109**:3451–6.
15. **Mjosberg JM**, Trifari S, Crellin NK, *et al.* Human IL-25- and IL-33-responsive type 2 innate lymphoid cells are defined by expression of CCR2 and CD161. *Nat Immunol* 2011;**12**:1055–62.
16. **Iwashita J**, Sato Y, Sugaya H, *et al.* mRNA of MUC2 is stimulated by IL-4, IL-13 or TNF-alpha through a mitogen-activated protein kinase pathway in human colon cancer cells. *Immunol Cell Biol* 2003;**81**:275–82.
17. **Wright K**, Kolios G, Westwick J, *et al.* Cytokine-induced apoptosis in epithelial HT-29 cells is independent of nitric oxide formation. Evidence for an interleukin-13-driven phosphatidylinositol 3-kinase-dependent survival mechanism. *J Biol Chem* 1999;**274**:17193–201.
18. **Atherton HC**, Jones G, Danahay H. IL-13-induced changes in the goblet cell density of human bronchial epithelial cell cultures: MAP kinase and phosphatidylinositol 3-kinase regulation. *Am J Physiol Lung Cell Mol Physiol* 2003;**285**:L730–9.
19. **Hecker M**, Zaslonka Z, Kwapiszewska G, *et al.* Dysregulation of the IL-13 receptor system: a novel pathomechanism in pulmonary arterial hypertension. *Am J Respir Crit Care Med* 2010;**182**:805–18.
20. **Andrews AL**, Holloway JW, Puddicombe SM, *et al.* Kinetic analysis of the interleukin-13 receptor complex. *J Biol Chem* 2002;**277**:46073–8.
21. **Kasaian MT**, Raible D, Marquette K, *et al.* IL-13 antibodies influence IL-13 clearance in humans by modulating scavenger activity of IL-13Ralpha2. *J Immunol* 2011;**187**:561–9.
22. **Yasunaga S**, Yuyama N, Arima K, *et al.* The negative-feedback regulation of the IL-13 signal by the IL-13 receptor alpha2 chain in bronchial epithelial cells. *Cytokine* 2003;**24**:293–303.
23. **Andrews AL**, Nasir T, Bucchieri F, *et al.* IL-13 receptor alpha 2: a regulator of IL-13 and IL-4 signal transduction in primary human fibroblasts. *J Allergy Clin Immunol* 2006;**118**:858–65.
24. **Rahaman SO**, Sharma P, Harbor PC, *et al.* IL-13R(alpha)2, a decoy receptor for IL-13 acts as an inhibitor of IL-4-dependent signal transduction in glioblastoma cells. *Cancer Res* 2002;**62**:1103–9.
25. **Barderas R**, Bartolome RA, Fernandez-Acenero MJ, *et al.* High expression of IL-13 receptor alpha2 in colorectal cancer is associated with invasion, liver metastasis, and poor prognosis. *Cancer Res* 2012;**72**:2780–90.
26. **Fichtner-Feigl S**, Strober W, Kawakami K, *et al.* IL-13 signaling through the IL-13alpha2 receptor is involved in induction of TGF-beta1 production and fibrosis. *Nat Med* 2006;**12**:99–106.
27. **Rahaman SO**, Vogelbaum MA, Haque SJ. Aberrant Stat3 signaling by interleukin-4 in malignant glioma cells: involvement of IL-13Ralpha2. *Cancer Res* 2005;**65**:2956–63.
28. **Chen W**, Tabata Y, Gibson AM, *et al.* Matrix metalloproteinase 8 contributes to solubilization of IL-13 receptor alpha2 in vivo. *J Allergy Clin Immunol* 2008;**122**:625–32.
29. **Matsumura M**, Inoue H, Matsumoto T, *et al.* Endogenous metalloprotease solubilizes IL-13 receptor alpha2 in airway epithelial cells. *Biochem Biophys Res Commun* 2007;**360**:464–9.
30. **Tabata Y**, Chen W, Warrier MR, *et al.* Allergy-driven alternative splicing of IL-13 receptor alpha2 yields distinct membrane and soluble forms. *J Immunol* 2006;**177**:7905–12.
31. **Kaser A**, Molnar C, Tilg H. Differential regulation of interleukin 4 and interleukin 13 production by interferon alpha. *Cytokine* 1998;**10**:75–81.
32. **Daines MO**, Hershey GK. A novel mechanism by which interferon-gamma can regulate interleukin (IL)-13 responses. Evidence for intracellular stores of IL-13 receptor alpha -2 and their rapid mobilization by interferon-gamma. *J Biol Chem* 2002;**277**:10387–93.
33. **Konstantinidis AK**, Puddicombe SM, Mochizuki A, *et al.* Cellular localization of interleukin 13 receptor alpha2 in human primary bronchial epithelial cells and fibroblasts. *J Investig Allergol Clin Immunol* 2008;**18**:174–80.
34. **Dickensheets HL**, Venkataraman C, Schindler U, *et al.* Interferons inhibit activation of STAT6 by interleukin 4 in human monocytes by inducing SOCS-1 gene expression. *Proc Natl Acad Sci USA* 1999;**96**:10800–5.
35. **Wu D**, Ahrens R, Osterfeld H, *et al.* Interleukin-13 (IL-13)/IL-13 receptor alpha1 (IL-13Ralpha1) signaling regulates intestinal epithelial cystic fibrosis transmembrane conductance regulator channel-dependent Cl⁻ secretion. *J Biol Chem* 2011;**286**:13357–69.
36. **Hering NA**, Fromm M, Schulzke JD. Determinants of colonic barrier function in inflammatory bowel disease and potential therapeutics. *J Physiol* 2012;**590**(Pt 5):1035–44.
37. **Bancroft AJ**, McKenzie AN, Grencis RK. A critical role for IL-13 in resistance to intestinal nematode infection. *J Immunol* 1998;**160**:3453–61.
38. **Urban JF Jr**, Noben-Trauth N, Donaldson DD, *et al.* IL-13, IL-4Ralpha, and Stat6 are required for the expulsion of the gastrointestinal nematode parasite *Nippostrongylus brasiliensis*. *Immunity* 1998;**8**(2):255–64.
39. **Else KJ**, Grencis RK. Antibody-independent effector mechanisms in resistance to the intestinal nematode parasite *Trichuris muris*. *Infect Immun* 1996;**64**:2950–4.
40. **Gaze S**, McSorley HJ, Daveson J, *et al.* Characterising the mucosal and systemic immune responses to experimental human hookworm infection. *PLoS Pathog* 2012;**8**:e1002520.
41. **Newcomb DC**, Boswell MG, Huckabee MM, *et al.* IL-13 regulates Th17 secretion of IL-17A in an IL-10-dependent manner. *J Immunol* 2012;**188**:1027–35.
42. **Newcomb DC**, Zhou W, Moore ML, *et al.* A functional IL-13 receptor is expressed on polarized murine CD4⁺ Th17 cells and IL-13 signaling attenuates Th17 cytokine production. *J Immunol* 2009;**182**:5317–21.
43. **Newcomb DC**, Boswell MG, Zhou W, *et al.* Human TH17 cells express a functional IL-13 receptor and IL-13 attenuates IL-17A production. *J Allergy Clin Immunol* 2011;**127**:1006–13 e1-4.
44. **Wilson MS**, Ramalingam TR, Rivollier A, *et al.* Colitis and intestinal inflammation in IL10^{-/-} mice results from IL-13Ralpha2-mediated attenuation of IL-13 activity. *Gastroenterology* 2011;**140**:254–64.
45. **Farmer DG**, Ke B, Shen XD, *et al.* Interleukin-13 protects mouse intestine from ischemia and reperfusion injury through regulation of innate and adaptive immunity. *Transplantation* 2011;**91**:737–43.
46. **Kucharzik T**, Luger N, Weigelt H, *et al.* Immunoregulatory properties of IL-13 in patients with inflammatory bowel disease; comparison with IL-4 and IL-10. *Clin Exp Immunol* 1996;**104**:483–90.
47. **Kolios G**, Wright KL, Linehan JD, *et al.* Interleukin-13 inhibits nitric oxide production in human colonic mucosa. *Hepatogastroenterology* 2000;**47**:714–17.
48. **Morimoto M**, Morimoto M, Zhao A, *et al.* Functional importance of regional differences in localized gene expression of receptors for IL-13 in murine gut. *J Immunol* 2006;**176**:491–5.
49. **Mandal D**, Levine AD. Elevated IL-13Ralpha2 in intestinal epithelial cells from ulcerative colitis or colorectal cancer initiates MAPK pathway. *Inflamm Bowel Dis* 2010;**16**:753–64.
50. **Heller F**, Florian P, Bojarski C, *et al.* Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution. *Gastroenterology* 2005;**129**:550–64.
51. **Scharl M**, Frei S, Pesch T, *et al.* Interleukin-13 and transforming growth factor beta synergise in the pathogenesis of human intestinal fistulae. *Gut* Published Online First: 27 Jan 2012. doi:10.1136/gutjnl-2011-300498
52. **McDermott JR**, Humphreys NE, Forman SP, *et al.* Intraepithelial NK cell-derived IL-13 induces intestinal pathology associated with nematode infection. *J Immunol* 2005;**175**:3207–13.
53. **Rothenberg ME**, Wen T, Shik D, *et al.* IL-13 receptor alpha1 differentially regulates aeroallergen-induced lung responses. *J Immunol* 2011;**187**:4873–80.
54. **Munitz A**, Brandt EB, Mingler M, *et al.* Distinct roles for IL-13 and IL-4 via IL-13 receptor alpha1 and the type II IL-4 receptor in asthma pathogenesis. *Proc Natl Acad Sci USA* 2008;**105**:7240–5.
55. **Corren J**, Lemanske RF, Hanania NA, *et al.* Lebrikizumab treatment in adults with asthma. *N Engl J Med* 2011;**365**:1088–98.
56. **Gauvreau GM**, Boulet LP, Cockcroft DW, *et al.* Effects of interleukin-13 blockade on allergen-induced airway responses in mild atopic asthma. *Am J Respir Crit Care Med* 2011;**183**:1007–14.

57. **Fuschioti P**, Medsger TA Jr, Morel PA. Effector CD8+ T cells in systemic sclerosis patients produce abnormally high levels of interleukin-13 associated with increased skin fibrosis. *Arthritis Rheum* 2009;**60**:1119–28.
58. **Oh MH**, Oh SY, Yu J, *et al*. IL-13 induces skin fibrosis in atopic dermatitis by thymic stromal lymphopoietin. *J Immunol* 2011;**186**:7232–42.
59. **Medsger TA Jr**, Ivanco DE, Kardava L, *et al*. GATA-3 up-regulation in CD8+ T cells as a biomarker of immune dysfunction in systemic sclerosis, resulting in excessive interleukin-13 production. *Arthritis Rheum* 2011;**63**:1738–47.
60. **Boirivant M**, Fuss IJ, Chu A, *et al*. Oxazolone colitis: a murine model of T helper cell type 2 colitis treatable with antibodies to interleukin 4. *J Exp Med* 1998;**188**:1929–39.
61. **Heller F**, Fuss IJ, Nieuwenhuis EE, *et al*. Oxazolone colitis, a Th2 colitis model resembling ulcerative colitis, is mediated by IL-13-producing NK-T cells. *Immunity* 2002;**17**:629–38.
62. **Scanlon ST**, Thomas SY, Ferreira CM, *et al*. Airborne lipid antigens mobilize resident intravascular NKT cells to induce allergic airway inflammation. *J Exp Med* 2011;**208**:2113–24.
63. **Camelo A**, Barlow JL, Drynan LF, *et al*. Blocking IL-25 signalling protects against gut inflammation in a type-2 model of colitis by suppressing nuocyte and NKT derived IL-13. *J Gastroenterol* Published Online First: 27 Apr 2012. doi: 10.1007/s00535-012-0591-2
64. **Rosen MJ**, Frey MR, Washington MK, *et al*. STAT6 activation in ulcerative colitis: a new target for prevention of IL-13-induced colon epithelial cell dysfunction. *Inflamm Bowel Dis* 2011;**17**:2224–34.
65. **Kawashima R**, Kawamura YI, Oshio T, *et al*. Interleukin-13 damages intestinal mucosa via TWEAK and Fn14 in mice—a pathway associated with ulcerative colitis. *Gastroenterology* 2011;**141**:2119–29 e8.
66. **Wood N**, Whitters MJ, Jacobson BA, *et al*. Enhanced interleukin (IL)-13 responses in mice lacking IL-13 receptor alpha 2. *J Exp Med* 2003;**197**:703–9.
67. **Vladich FD**, Brazille SM, Stern D, *et al*. IL-13 R130Q, a common variant associated with allergy and asthma, enhances effector mechanisms essential for human allergic inflammation. *J Clin Invest* 2005;**115**:747–54.
68. **DeMeo DL**, Lange C, Silverman EK, *et al*. Univariate and multivariate family-based association analysis of the IL-13 ARG130GLN polymorphism in the Childhood Asthma Management Program. *Genet Epidemiol* 2002;**23**:335–48.
69. **Granel B**, Chevillard C, Allanore Y, *et al*. Evaluation of interleukin 13 polymorphisms in systemic sclerosis. *Immunogenetics* 2006;**58**:693–9.
70. **Heinzmann A**, Mao XQ, Akaiwa M, *et al*. Genetic variants of IL-13 signalling and human asthma and atopy. *Hum Mol Genet* 2000;**9**:549–59.
71. **Howard TD**, Whittaker PA, Zaiman AL, *et al*. Identification and association of polymorphisms in the interleukin-13 gene with asthma and atopy in a Dutch population. *Am J Respir Cell Mol Biol* 2001;**25**:377–84.
72. **Waterman M**, Karban A, Nesher S, *et al*. (The significance of IL-13 gene +2044G/A mutation in patients with inflammatory bowel disease). *Harefuah* 2006;**145**:789–92, 864.
73. **Arijs I**, Li K, Toedter G, *et al*. Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis. *Gut* 2009;**58**:1612–19.
74. **Bakshi S**, Zhang X, Godoy-Tundidor S, *et al*. Transcriptome analyses in normal prostate epithelial cells exposed to low-dose cadmium: oncogenic and immunomodulations involving the action of tumor necrosis factor. *Environ Health Perspect* 2008;**116**:769–76.
75. **Mannon PJ**, Hornung RL, Yang Z, *et al*. Suppression of inflammation in ulcerative colitis by interferon-beta-1a is accompanied by inhibition of IL-13 production. *Gut* 2011;**60**:449–55.
76. **Gonsalves N**, Yang GY, Doerfler B, *et al*. Elimination diet effectively treats eosinophilic esophagitis in adults; food reintroduction identifies causative factors. *Gastroenterology* 2012;**142**:1451–9 e1.
77. **Mishra A**, Rothenberg ME. Intratracheal IL-13 induces eosinophilic esophagitis by an IL-5, eotaxin-1, and STAT6-dependent mechanism. *Gastroenterology* 2003;**125**:1419–27.
78. **Akei HS**, Mishra A, Blanchard C, *et al*. Epicutaneous antigen exposure primes for experimental eosinophilic esophagitis in mice. *Gastroenterology* 2005;**129**:985–94.
79. **Zuo L**, Fulkerson PC, Finkelman FD, *et al*. IL-13 induces esophageal remodeling and gene expression by an eosinophil-independent, IL-13R alpha 2-inhibited pathway. *J Immunol* 2010;**185**:660–9.
80. **Neilsen CV**, Bryce PJ. Interleukin-13 directly promotes oesophagus production of CCL11 and CCL24 and the migration of eosinophils. *Clin Exp Allergy* 2010;**40**:427–34.
81. **Blanchard C**, Stucke EM, Rodriguez-Jimenez B, *et al*. A striking local esophageal cytokine expression profile in eosinophilic esophagitis. *J Allergy Clin Immunol* 2011;**127**:208–17, 17 e1–7.
82. **Frischmeyer-Guerrero PA**, Guerrero AL, Chichester KL, *et al*. Dendritic cell and T cell responses in children with food allergy. *Clin Exp Allergy* 2011;**41**:61–71.
83. **Sherrill JD**, Rothenberg ME. Genetic dissection of eosinophilic esophagitis provides insight into disease pathogenesis and treatment strategies. *J Allergy Clin Immunol* 2011;**128**:23–32; quiz 3–4.
84. **Blanchard C**, Stucke EM, Burwinkel K, *et al*. Coordinate interaction between IL-13 and epithelial differentiation cluster genes in eosinophilic esophagitis. *J Immunol* 2010;**184**:4033–41.
85. **Matsushita M**, Yamamoto T, Nishioka K. Upregulation of interleukin-13 and its receptor in a murine model of bleomycin-induced scleroderma. *Int Arch Allergy Immunol* 2004;**135**:348–56.
86. **Ricciardi V**, Rinaldi T, Spadaro A, *et al*. Interleukin-13 in systemic sclerosis: relationship to nailfold capillaroscopy abnormalities. *Clin Rheumatol* 2003;**22**:102–6.
87. **Chiaromonte MG**, Donaldson DD, Cheever AV, *et al*. An IL-13 inhibitor blocks the development of hepatic fibrosis during a T-helper type 2-dominated inflammatory response. *J Clin Invest* 1999;**104**:777–85.
88. **Wallace WA**, Ramage EA, Lamb D, *et al*. A type 2 (Th2-like) pattern of immune response predominates in the pulmonary interstitium of patients with cryptogenic fibrosing alveolitis (CFA). *Clin Exp Immunol* 1995;**101**:436–41.
89. **Zhu Z**, Homer RJ, Wang Z, *et al*. Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production. *J Clin Invest* 1999;**103**:779–88.
90. **Wilson MS**, Wynn TA. Pulmonary fibrosis: pathogenesis, etiology and regulation. *Mucosal Immunol* 2009;**2**:103–21.
91. **Lee CG**, Homer RJ, Zhu Z, *et al*. Interleukin-13 induces tissue fibrosis by selectively stimulating and activating transforming growth factor beta(1). *J Exp Med* 2001;**194**:809–21.
92. **Edwards FC**, Truelove SC. The course and prognosis of ulcerative colitis. III. Complications. *Gut* 1964;**5**:1–22.
93. **Gumaste V**, Sachar DB, Greenstein AJ. Benign and malignant colorectal strictures in ulcerative colitis. *Gut* 1992;**33**:938–41.
94. **Maul J**, Zeitz M. Ulcerative colitis: immune function, tissue fibrosis and current therapeutic considerations. *Langenbecks Arch Surg* 2012;**397**:1–10.
95. **Akiho H**, Deng Y, Blennerhassett P, *et al*. Mechanisms underlying the maintenance of muscle hypercontractility in a model of postinfective gut dysfunction. *Gastroenterology* 2005;**129**:131–41.
96. **Mizutani T**, Akiho H, Khan W, *et al*. Persistent gut motor dysfunction in a murine model of T-cell-induced enteropathy. *Neurogastroenterol Motil* 2010;**22**:196–203, e65.
97. **Kindt S**, Van Oudenhove L, Broekaert D, *et al*. Immune dysfunction in patients with functional gastrointestinal disorders. *Neurogastroenterol Motil* 2009;**21**:389–98.
98. **May RD**, Monk PD, Cohen ES, *et al*. Preclinical development of CAT-354, an IL-13 neutralizing antibody, for the treatment of severe uncontrolled asthma. *Br J Pharmacol* 2012;**166**:177–93.
99. **Kasaian MT**, Tan XY, Jin M, *et al*. Interleukin-13 neutralization by two distinct receptor blocking mechanisms reduces immunoglobulin E responses and lung inflammation in cynomolgus monkeys. *J Pharmacol Exp Ther* 2008;**325**:882–92.
100. **Nakashima H**, Husain SR, Puri RK. IL-13 receptor-directed cancer vaccines and immunotherapy. *Immunotherapy* 2012;**4**:443–51.
101. **Mannon P**, Miner PB, Lukas M, *et al*. Secondary efficacy analysis from a phase IIa multicenter study with interferon- β -1a for induction of clinical response in active moderate to severe ulcerative colitis. *Am J Gastroenterol* 2010;**105**:S446.
102. **Piper E**, Brightling C, Niven R, *et al*. Phase 2 randomized, double-blind, placebo-controlled study of tralokinumab, an anti-IL-13 monoclonal antibody, in moderate to severe asthma. *Eur Respir J* Published Online First: 27 Jun 2012. doi:10.1183/09031936.00223411 abstract 3425.
103. **Nicholson GC**, Kariyawasam HH, Tan AJ, *et al*. The effects of an anti-IL-13 mAb on cytokine levels and nasal symptoms following nasal allergen challenge. *J Allergy Clin Immunol* 2011;**128**:800–7, e9.
104. **Ying H**, Miller R, Bose S, *et al*. ABT-308, A highly potent anti-IL-13 therapeutic antibody for the treatment of human asthma. *Am J Respir Crit Care Med* 2010;**181**:A6644.
105. **Corren J**, Busse W, Meltzer EO, *et al*. A randomized, controlled, phase 2 study of AMG 317, an IL-4/IL-13 antagonist, in patients with asthma. *Am J Respir Crit Care Med* 2010;**181**:788–96.
106. **Kakkar T**, Sung C, Gibiansky L, *et al*. Population PK and IgE pharmacodynamic analysis of a fully human monoclonal antibody against IL4 receptor. *Pharm Res* 2011;**28**:2530–42.
107. **Wenzel S**, Wilbraham D, Fuller R, *et al*. Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies. *Lancet* 2007;**370**:1422–31.
108. **Otulana BA**, Wenzel SE, Ind PW, *et al*. A phase 2b study of inhaled pitrakinra, an IL-4/IL-13 antagonist, successfully identified responder subpopulations of patients with uncontrolled asthma. *Am J Respir Crit Care Med* 2011;**183**:A6179.
109. **Wenzel SE**, Ind PW, Otulana BA, *et al*. Inhaled pitrakinra, an IL-4/IL-13 antagonist, reduced exacerbations in patients with eosinophilic asthma. *Eur Respir Soc Annual Congress* 2010:abstract 3980.
110. **Slager RE**, Hawkins GA, Ampleford EJ, *et al*. IL-4 receptor alpha polymorphisms are predictors of a pharmacogenetic response to a novel IL-4/IL-13 antagonist. *J Allergy Clin Immunol* 2010;**126**:875–8.
111. **Hodges M**, Castelloe E, Chen A, *et al*. A phase 1 multiple dose safety and pharmacokinetics study of AIR645, an inhaled IL-4 α 2-MOE GAPMER oligonucleotide. *Eur Respir Soc Annual Congress* 2009:abstract 1800.
112. **Hodges MR**, Castelloe E, Chen A, *et al*. Randomized, double-blind, placebo controlled first in human study of inhaled AIR645, an IL-4R[alpha] oligonucleotide, in healthy volunteers. *Am J Respir Crit Care Med* 2009;**179**:A3640.